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Abstract
Background: Tetrahydrobiopterin (BH4) deficiencies comprise a group of six rare neurometabolic disorders
characterized by insufficient synthesis of the monoamine neurotransmitters dopamine and serotonin due to a
disturbance of BH4 biosynthesis or recycling. Hyperphenylalaninemia (HPA) is the first diagnostic hallmark for most BH4
deficiencies, apart from autosomal dominant guanosine triphosphate cyclohydrolase I deficiency and sepiapterin
reductase deficiency. Early supplementation of neurotransmitter precursors and where appropriate, treatment of HPA
results in significant improvement of motor and cognitive function. Management approaches differ across the world
and therefore these guidelines have been developed aiming to harmonize and optimize patient care. Representatives
of the International Working Group on Neurotransmitter related Disorders (iNTD) developed the guidelines according to
the SIGN (Scottish Intercollegiate Guidelines Network) methodology by evaluating all available evidence for the
diagnosis and treatment of BH4 deficiencies.
Conclusion: Although the total body of evidence in the literature was mainly rated as low or very low, these consensus
guidelines will help to harmonize clinical practice and to standardize and improve care for BH4 deficient patients.
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Tetrahydrobiopterin (BH4) deficiencies comprise a group
of six rare neurometabolic disorders caused by pathogenic
variants in five genes responsible for the biosynthesis and
regeneration of BH4, which is the essential cofactor of the
aromatic amino acid hydroxylases phenylalanine hydroxy-
lase (PAH), tyrosine hydroxylase (TH), two isoforms of
tryptophan hydroxylase (TPH 1/2), alkylglycerol mono-
oxygenase (AGMO), as well as of three isoforms of nitric
oxide synthase (NOS 1–3) (Fig. 1). Since TH and TPH are
key enzymes in the synthesis of the monoamines dopa-
mine, serotonin, norepinephrine, and epinephrine, a dis-
turbance of BH4 metabolism results in a severe depletion
of all monoamine neurotransmitters. In addition, as PAH
mediates the conversion of phenylalanine (Phe) to tyrosine
(Tyr), hyperphenylalaninemia (HPA) is present in all BH4
deficiencies apart from autosomal dominant guanosine
triphosphate cyclohydrolase I deficiency (AD-GTPCHD)
and sepiapterin reductase deficiency (SRD) [1, 2]. AD-
GTPCHD is the most common cause of dopa-responsive
dystonia (DRD), a clinical syndrome characterized by dys-
tonia that fluctuates diurnally and responds very well to
treatment with levodopa (L-Dopa). AD-GTPCHD is also
called autosomal dominant Segawa syndrome (DYT5a),
whereas autosomal recessive Segawa syndrome is usually
caused by autosomal recessive mutations of the TH gene
(DYT5b).
BH4 synthesis and regeneration is a multistage process
involving a series of steps catalysed by five enzymes.
Guanosine triphosphate cyclohydrolase I (GTPCH, EC
3.5.4.16), 6-pyruvoyltetrahydropterin synthase (6-PTPS,
EC 4.2.3.12), and sepiapterin reductase (SR, EC 4.1.1.17)
are the enzymes for BH4 biosynthesis. Pterin-4-alpha-
carbinolamine dehydratase (PCD, EC 4.2.1.96) and q-
dihydropteridine reductase (DHPR, EC 1.5.1.34) ensure
BH4 regeneration (Fig. 1). All the disorders are inherited
in an autosomal recessive (AR) manner, apart from
GTPCH deficiency (GTPCHD), which manifests with
both autosomal recessive and autosomal dominant (AD)
inheritance patterns (Table 1).
The precise global prevalence of BH4 deficiencies re-
mains unknown and great variance can be found among
different countries [3, 4]. The mean incidence of all
HPAs detected by newborn screening (NBS) pro-
grammes in Europe is estimated to be approximately 1:
10000 [5], and BH4 deficiencies are presumed to
constitute around 1–2% of these cases. PTPS deficiency
(PTPSD) is the most frequent of all HPA -associated
BH4 deficiencies (approx. 54%), followed by DHPR defi-
ciency (DHPRD, approx. 33%) [3]. For AD-GTPCHD a
prevalence of 2.96 per million was stated [6], however,
since many publications do not clearly classify the dis-
ease into DRD, AD or AR Segawa syndrome, and do not
always mention the underlying gene mutations, a final
assessment of the prevalence is not possible [7]. There
seems to be a high rate of undiagnosed patients [8-10].
Recently, a novel disorder to be included in the differen-
tial diagnosis of HPA has been identified: the disorder is
caused by biallelic mutations in the DNAJC12 gene and
is associated with a variable neurological phenotype in
association with HPA [11, 12].
Both laboratory and clinical findings in patients with
BH4 deficiencies are attributable to two main pathophys-
iologic mechanisms: HPA, and depletion of the
monoamine neurotransmitters in the central nervous
system (CNS).
Cerebral HPA toxicity is multifactorial. The most
prominent hypotheses discussed include: 1) competitive
inhibition of a blood-brain-barrier (BBB) transporter of
large neutral amino acids (LNAA) including tyrosine
and tryptophan with decreased protein and neurotrans-
mitter synthesis; 2) decreased cholesterol synthesis and
myelin production, as well as direct myelin toxicity; 3)
tyrosine and tryptophan hydroxylase inhibition; 4) oxida-
tive stress; 5) complex reduction of glutamatergic synap-
tic transmission; 6) pyruvate kinase inhibition; 7)
calcium homeostasis dysregulation [5, 13].
The second, and clinically dominant, pathophysiological
mechanism of neurological dysfunction in the BH4 defi-
ciencies is shortage of the brain neurotransmitters dopa-
mine, serotonin, and norepinephrine. Dopamine is most
commonly associated with the control of voluntary move-
ment and reward-based learning and behaviour [14]. Nor-
epinephrine is the modulator of arousal [15] and
serotonin affects predominantly higher cognitive functions
and behaviour. However, deeper insight into the complex-
ity of CNS neurotransmission reveals that monoaminergic
neurons and their neurotransmitters share many common
properties, greatly overlap in numerous functions, and are
highly orchestrated to jointly modulate numerous brain
processes. As a result, dopamine, serotonin, and norepin-
ephrine are all implicated in the modulation of higher cog-
nitive and executive function, behaviour, mood, attention,
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pain perception, motor control, and many other brain
processes [16]. Attribution of any given clinical symp-
tom to the deficiency of a single neurotransmitter is
therefore likely to be an over-simplification. However,
the general signs of dopamine deficiency include pre-
dominantly parkinsonism, and dystonic movements, in
young infants also tremorous or choreatiform and
various other involuntary movements, while seroto-
ninergic deficiency is thought to manifest as sleep pat-
tern disturbance, mood dysregulation and temperature
instability [17].
Following the two main underlying pathophysiologic
pathways, treatment strategies primarily aim at the cor-
rection of peripheral HPA and brain neurotransmitter
Fig. 1 Biosynthesis and regeneration of tetrahydrobiopterin (BH4) and its functions as cofactor in the synthesis of serotonin, dopamine, and other
catecholamines as well as the catabolism of phenylalanine. Simplified scheme of the biosynthesis and regeneration of tetrahydrobiopterin (BH4)
in the presynaptic axonal end. BH4 serves as essential cofactor of the aromatic amino acid hydroxylases phenylalanine hydroxylase (PAH), tyrosine
hydroxylase (TH), and tryptophan hydroxylase (TPH) which catalyse key reactions in the synthesis of the monoamines dopamine, serotonin,
norepinephrine, and epinephrine. Note that AGMO and NOSs are not depicted in this overview. 5-HIAA, 5-hydroxyindoleacetic acid; 5-HIAL, 5-
hydroxyindoleacetaldehyde; 7,8-BH2, 7,8-dihydrobiopterin; BH4, tetrahydrobiopterin; DOPAC, 3,4-dihydroxyphenylacetic acid; DOPAL, 3,4-
dihydroxyphenylacetaldehyde; DTDS, dopamine transport deficiency syndrome; GTP, guanosine-5′-triphosphate; HVA, homovanillic acid; Oxo-
PH41, oxo-2-hydroxy-tetrahydropterin; PLP, pyridoxal 5′-phosphate; PTP, 6-pyruvoyltetrahydropterin; qBH2, quinonoid dihydrobiopterin; VLA,
vanillyllactic acid; VMA, vanillylmandelic acid; VMAT 2, vesicular monoamine transporter
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deficiencies. We developed this first consensus guideline
for the diagnosis and management of BH4 deficiencies in
the context of the International Working Group on
Neurotransmitter Related Disorders (iNTD, www.intd-on-
line.org) and by using the Scottish Intercollegiate Guide-
line Network (SIGN) methodology. The recommendations
are based on a systematic review of the available literature
and on consensus meetings of the iNTD guideline work-
ing group. The guideline is intended for metabolic special-
ists, child and adult neurologists, paediatricians, intensive
care specialists, nurses, and paramedical specialists in-
volved in the care of patients with BH4 deficiencies.
Methods
Composition of the guideline working group and timeline
An executive committee (TO (chairman), OKH (secre-
tary, subgroup coordinator), ELL, ECS, JK (subgroup co-
ordinators) and KJ (project coordination)) was appointed
to oversee the guideline development process. Four dif-
ferent subgroups were generated, headed by one of the
subgroup coordinators (AR/AD GTPCHD (ELL), PTPSD
(JK), DHPRD (ECS) and PCDD/SRD (OKH)). The guide-
line working group consisted of 24 child neurologists
and/or metabolic specialists (TO, ELL, ECS, TP, SSB,
BA, MK, VL, WL, FP, AGC, TH, RP, LR, HG, GFH, GH,
SBB, AB, MM, JF, TW, JK, OKH), 5 biochemists (RA,
BT, SH, SP, MV), and 1 research project manager (KJ)
from several European countries, the USA and Canada.
All group members are part of the iNTD network and
experienced in the diagnosis and treatment of BH4 defi-
ciencies. The project was supported by patient organiza-
tions (see below, section on “Patient advocacy groups”).
The start-up meeting took place in Barcelona, Spain in
February 2017, followed by one meeting of the subgroup
coordinators in Heidelberg, Germany in November 2017
and a face-to-face meeting for the whole guideline group
in Athens, Greece in September 2018 (at the meeting of
the Society for the Study of Inborn Errors of Metabolism
(SSIEM)).
In adherence to Scottish Intercollegiate Guidelines
Network (SIGN) methodology, two external academic
reviewers with expertise in neurometabolic and move-
ment disorders (Nicola Longo, Salt Lake City, USA and
Keith Hyland, Atlanta, USA) and additional lay reviewers
(Pauline Schleicher, Melanie Kahlo and Ivana Badnjare-
vic) were asked to comment on the guideline draft be-
fore submission.
Developing topics and key questions
During the start-up meeting, the list of key questions
was discussed and refined. Key questions comprised the
following topics: Clinical Presentation, Diagnosis (la-
boratory tests, imaging, electrophysiological investiga-
tions, etc.), Treatment, Management of Complications
and Long-Term Follow-Up, Social Issues, and Transition
(Additional file 1: Table S1). All topics were considered
by each of the 4 different BH4 disorder subgroups.
Systematic literature search
A systematic literature review on BH4 and related names
was performed in spring 2017 on Pubmed, Cochrane
database, and the Cinahl database, using the following
search terms: “Tetrahydrobiopterin deficiency”, “BH4 de-
ficiency”, “atypical PKU”, “atypical phenylketonuria”,
“PTPS deficiency”, “(6-)pyruvoyl-tetrahydropterin syn-
thase deficiency”, “SR deficiency”, “sepiapterin reductase
deficiency”, “segawa(s) disease”, “GTPCH (I) deficiency”,
“GTP cyclohydrolase (I) deficiency”,“Guanosine (-5-) tri-
phosphate cyclohydrolase (I) deficiency”,” DHPR
Table 1 Nomenclature of BH4 disorders

















GCH1 AD GTPCH I 128230
Autosomal recessive GTP cyclohydrolase I
deficiency
– AR-GTPCHD, DYT/PARK-GCH1 GCH1 AR GTPCH I 233910
6-pyruvoyl-tetrahydropterin synthase
deficiency
– PTPSD, DYT/PARK-PTS PTS AR PTPS 261640
Sepiapterin reductase deficiency – SRD, DYT/PARK-SPR SPR AR SR 612716
Q-dihydropteridine reductase deficiency – DHRPD, DYT/PARK-QDPR QDPR AR DHPR 261630
Pterin-4-alpha-carbinolamine dehydratase
deficiency
Primapterinuria PCDD PCBD1 AR PCD 264070
Abbreviations in the table: AR Autosomal recessive, AD Autosomal dominant, DHPRD Dihydropteridine reductase deficiency, GCH1 GTP cyclohydrolase 1, GTPCHD
Guanosine triphosphate cyclohydrolase I deficiency, PCBD1 Pterin-4 alpha-carbinolamine dehydratase, PCDD Pterin-4-alpha-carbinolamine dehydratase deficiency,
PTPSD 6-pyruvoyl-tetrahydropterin synthase deficiency, PTS 6-Pyruvoyltetrahydropterin synthase, QDPR Quinoid dihydropteridine reductase, SR Sepiapterin
reductase, SRD Sepiapterin reductase deficiency
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deficiency”, “dihydropteridine reductase deficiency”,
“pterin (-4a-) carbinolamine dehydratase deficiency”,
“PCD deficiency“. No language or data filters were used.
Single newly published manuscripts with clear clinical
relevance for the guideline development were included in
the literature database until the end of guideline develop-
ment process. Reference lists from review articles and key
case series were screened for additional hits and members
of the guideline group were asked to suggest relevant book
chapters. The flow chart in the supplementary material il-
lustrates the literature search (Additional file 2: Figure S2).
Grading of evidence and recommendations
The guideline was developed according to method-
ology of the SIGN [18]. For rating the quality of evi-
dence and defining the strength of recommendations,
SIGN is committed to using the Grading of Recom-
mendations, Assessment, Development and Evaluation
(GRADE) methodology. The level of evidence of indi-
vidual studies was rated from 4 (lowest) to 1++ (high-
est). Specific outcomes (e.g. effect of a specific drug
on hypotonia) were described in relation to the qual-
ity of evidence (very low, low, moderate or high) for
the total body of evidence. Recommendations were
rated as strong (for or against), conditional (for or
against), or classified with a recommendation for fur-
ther research (Table 2).
Furthermore, Good Practice Points (GPP) were for-
mulated based on the clinical experience of the guide-
line development group. Relevant papers were
evaluated by at least two guideline working group
members. Before and during meetings, the guideline
group members were trained in standardized literature
evaluation using SIGN/GRADE methodologies. All rec-
ommendations were discussed for consensus during
guideline group meetings.
Disclaimer
The purpose of this guideline is to improve care for pa-
tients with BH4 deficiencies. It is not intended to replace
sensible, well-informed clinical care. Although the guide-
line is based on the best available evidence, the body of
evidence for these disorders is comprised mainly of non-
analytical studies and case reports. In addition, some
recommendations reflect expert, often consensus opin-
ion. Nevertheless, we believe that this guideline, which is
meant to provide a solid foundation to caregivers of BH4
deficient patients, will improve the care for these pa-
tients around the world.
Clinical presentation
The data on the clinical phenotype of BH4 deficiencies
(BH4Ds) was collected from a retrospective analysis of
published case reports. The level of precision and profi-
ciency regarding the recognition and the use of medical
terminology to describe clinical symptoms varied sub-
stantially among individual publications, resulting in a
certain level of imprecision. After the establishment of
the first registry on BH4Ds with HPA which gathered
clinical, biochemical, and treatment data (Database of
Patients and Genotypes Causing HPA/Phenylketonuria
(PKU) incl. BH4-Responsive Phenotype, BIODEF; http://
www.biopku.org/home/biodef.asp), more precise infor-
mation on case series could be obtained for AR-
GTPCHD, PTPSD, DHPRD and PCDD [3, 19]. Since
2015, the International Working Group on Neurotrans-
mitter related Disorders (iNTD; http://www.iNTD-on-
line.org) provides the first patient registry for all
neurotransmitter - related disorders with a standardized
longitudinal assessment of complex patient data [20].
General clinical pattern of BH4Ds and differential
diagnosis
The cardinal symptoms of BH4Ds reflect dopamine defi-
ciency as well as the imbalance of other neurotransmit-
ters including serotonin, norepinephrine or epinephrine
in the CNS (Table 3). While the overall clinical pheno-
type of BH4Ds may overlap with numerous other disor-
ders, e.g. cerebral palsy [21], certain clinical features may
raise the clinical suspicion for a disorder of impaired
neurotransmission (e.g. early onset parkinsonism, oculo-
gyric crises, diurnal fluctuation of symptoms, or an un-
explained cerebral palsy-like picture). It is important to
note that patients may show a wide spectrum of clinical
Table 2 Forms of recommendations
Judgment Recommendation
Undesirable consequences clearly outweigh desirable consequences Strong recommendation against
Undesirable consequences probably outweigh desirable
consequences
Conditional recommendation against
Balance between desirable and undesirable consequences is closely
balanced or uncertain
Recommendation for research and possibly conditional recommendation
for use restricted to trials
Desirable consequences probably outweigh undesirable
consequences
Conditional recommendation for
Desirable consequences clearly outweigh undesirable consequences Strong recommendation for
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Table 3 Symptoms and signs described in the different BH4 deficiencies
PTPSD DHPRD AR-GTPCHD SRD PCDD AD-GTPCHD
Number of reported cases 125 77 55 53 19 570
Nervous system
Developmental delay +++ +++ +++ +++ + (+)
(Axial) Hypotonia +++ ++ +++ +++ + (+)
Poor head control + + + + (+)
Hypertonia ++ ++ ++ ++ (+) ++
Epilepsy ++ +++ + +
Cognitive impairment ++ + (+) ++ (+)
Impaired speech development + (+) (+) +++ (+)
Dysarthria (+) (+) +++ (+)
Movement disorders
Diurnal fluctuation of symptoms + +++ +++
Dystonia + + ++ +++ +++
Oculogyric crises (+) + (+) +++ (+)
Gait difficulties +++
Dyskinesia/other involuntary movements + + (+) +/++
Parkinsonism/hypokinesia + (+)/+ + +++ +
Tremor (+) (+) (+) (+) +
Ataxia (+) (+) + (+)
Other
Hyperreflexia (+)/+ + ++
Irritability (+)/+ +
Microcephaly ++ (+) (+)
Autonomous nervous system
Temperature instability (+) (+) ++ ++
Gastrointestinal system
Hypersalivation (+) + ++ +/++
Feeding/swallowing difficulties + + (+) ++ (+)
Psychological problems
Behavioural problems (+) (+) (+)
Psychiatric problems (+) (+) ++ +
Sleep problems (+) (+) ++ (+)
Endocrine disturbances
Growth-hormone deficiency (+)




Microcephaly ++ (+) (+)
Fatigability (+) + (+) (+)
Recurrent chest infections +
Prematurity + +
Hypomagnesemia +
Symptoms and signs reported in 570 Patients with AD-GTPCHD, 55 patients with AR-GTPCHD, 125 patients with PTPSD, 77 patients with DHPRD, 53
patients with SRD and 19 patients with PCDD
Very frequently +++ (≥50%), frequently ++ (≥25- < 50%), infrequently + (≥10- < 25%), occasionally (+) (< 10%)
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severity, ranging from asymptomatic individuals requir-
ing no treatment to very severe disease courses.
Clinical patterns specific of PTPSD, DHPRD, AR-GTPCHD,
and SRD
The most common symptoms prior to treatment initi-
ation were assessed in 125 PTPSD, 77 DHPRD, 55 AR-
GTPCHD and 53 SRD patients. Hypotonia, impaired
motor development and cognitive development, move-
ment disorders (mainly dystonia), and parkinsonism/
hypokinetic rigid syndrome (consisting of bradykinesia,
extrapyramidal rigidity (“cogwheel rigidity”), rest tremor
and/or postural instability) are the hallmarks of BH4Ds
and should prompt clinicians to include BH4Ds in the
differential diagnosis.
Table 3 summarizes frequencies of the individual
symptoms: Approximately 50–75% of patients with any
of these disorders have hypotonia, often combined with
poor head control and peripheral hypertonia, mainly of
the extremities. Developmental delay of variable severity
is another common symptom, described in > 50% of pa-
tients. Specific impairment of cognitive and speech de-
velopment was reported in around 50% of SRD and
PTPSD patients and in substantially lower proportions
(5–15%) in the remaining BH4Ds. However, it should be
noted that in most studies, standardized neuropsycho-
logical assessment is lacking, so that there is a risk of
over- or underestimating cognitive function.
Movement disorders, mainly dystonia, have been re-
ported in almost 60% of patients with SRD, but less fre-
quently in other BH4Ds (10–35%). Oculogyric crises
were reported in 60% of patients with SRD and only in
5–15% of patients with DHPRD, AR-GTPCHD and
PTPSD. It is important to note that the SRD cohort is
comprised of patients whose clinical features have been
very precisely characterized. Therefore, it should be kept
in mind that these symptoms, as well as those described
below, may be just as common or even more common
in the BH4Ds other than SRD, but underestimated in
published reports where patients’ clinical phenotypes
were less precisely characterized.
Dyskinesia or other types of involuntary movements
such as rest/postural tremor were not frequent and oc-
curred predominantly in SRD patients. Ataxia is not
often reported in any of the BH4D patient groups.
Early-onset parkinsonism or hypokinetic rigid syn-
drome is associated with only a limited differential diag-
nosis in infancy and childhood, and should prompt
clinicians to include investigations for BH4Ds in the
diagnostic approach. Parkinsonism or hypokinetic rigid
syndrome was identified in around 60% of SRD, 25% of
PTPSD, and 10% of DHPRD and AR-GTPCHD patients.
Diurnal fluctuation of movement symptoms (worsening
over the course of the day; subsequent improvement
after rest) is generally regarded as characteristic of
neurotransmitter disorders. It was, however, reported in
68% of patients with SRD and only around 10% of pa-
tients with AR-GTPCHD.
Patients with DHPRD in particular may develop epi-
leptic seizures, while seizures are less common in pa-
tients with PTPSD, and occur rarely in SRD and AR-
GTPCHD. No specific type of epilepsy was identified.
Interestingly, roughly 10% of patients with PTPSD and
DHPRD were reported to have irritability and hyperre-
flexia, while these symptoms were reported in neither
SRD nor AR-GTPCHD.
Autonomic dysregulation, reflecting the disruption of
neurotransmitter homeostasis and most frequently man-
ifesting as temperature instability, was documented pri-
marily in SRD and AR-GTPCHD (almost 35%).
Excessive salivation was regularly reported in all BH4D,
again most commonly in AR-GTPCHD and SRD (25–
40%), and less frequently in DHPRD and PTPSD (5–
15%). Swallowing/feeding difficulties, presumably due to
overall motor impairment and/or oropharyngeal dys-
tonia, were seen in 20 to 30% of patients with SRD,
PTPS and DHPRD.
Single case reports add endocrine dysfunction like
growth-hormone deficiency (PTPSD) or central
hypothyroidism (SRD) to the clinical phenotype [22, 23].
An increased frequency of prematurity has been re-
ported in PTPSD and DHPRD. In PTPSD, a tendency
towards low birth weight has been observed [3]. Up to
25% of patients with DHPRD were reported to be micro-
cephalic, as opposed to the other disorders, in which
microcephaly was reported in only 1% of patients.
Various psychiatric and behavioural problems (includ-
ing depression, anxiety, psychosis, obsessive compulsive
features, impulsivity, and attention deficit disorder) as
well as sleep disturbance are reported infrequently in all
of the BH4Ds. However, psychiatric and behavioural
problems are likely underdiagnosed, except in SRD,
where they were documented in around 45% of patients
[21, 24–28].
R#1: (strong): In patients with unexplained alterations
in muscle tone (hypotonia/hypertonia), movement disor-
ders (dystonia, oculogyric crises), parkinsonism or hypo-
kinetic rigid syndrome, autonomic dysfunction or
diurnal fluctuation of symptoms, BH4Ds should be
considered.
R#2: (strong): Clinical follow-up should include the
assessment of psychiatric or behavioural problems and
sleep disorders.
Clinical patterns specific to PCDD
PCDD represents the rarest BH4D. A clear clinical de-
scription has been documented in the literature in only
19 patients (Table 3). In the BIODEF database most
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patients were reported to be asymptomatic (as of
01.05.2019), although a few patients exhibited transient
alterations in muscle tone, slight tremor or transient and
very mild delay in motor development [29]. However,
mutations in PCBD1 are associated with both hypomag-
nesaemia and risk for HNF1A-like Maturity Onset Dia-
betes of the Young (MODY3) diabetes in puberty [30],
so patients with PCBD1 mutations should be screened
for these disorders.
R#3: (strong): Patients with PCDD should be screened
for hypomagnesaemia and the development of HNF1A-
like MODY3 diabetes during puberty.
Specific clinical pattern of AD-GTPCHD
Data regarding the clinical spectrum of AD-GTPCHD
prior to treatment initiation was reviewed in 570 pa-
tients (Table 3). Clinical symptoms in AD-GTPCHD
differ substantially in many aspects from the
remaining BH4Ds. The phenotype is milder and in
more than 50% of cases dominated by postural or
action-induced dystonia of one or both lower limbs
manifesting as gait difficulties. Diurnal fluctuation of
motor symptoms, with worsening later in the day, is
a very characteristic finding in AD-GTPCHD, espe-
cially during the first 3 decades [9]. Later, fluctuations
become less prominent. If not treated, focal or seg-
mental dystonia typically progresses to multifocal or
even generalized dystonia (observed in 15%), together
with the development of parkinsonian signs in some
cases (reported in 13%). The clinical presentation in
the second decade of life is characterized by action
dystonia of the upper limbs, sometimes associated
with cervical impairment, asymmetric tremor and par-
kinsonism [8]. After the age of 20 years the predomin-
ant (> 80%) presentation is parkinsonism (isolated or
combined with dystonia). The progression of the dys-
tonia (in both symptom severity and spread of symp-
toms to previously unaffected body parts) and the
diurnal fluctuation of symptoms subside with age and
the disease becomes almost stable in the fourth dec-
ade. Increased risk of typical degenerative parkinson-
ism has been reported in adulthood with rare GCH1
variants [31]. Psychiatric disorders have been reported
in 10% of patients. Other symptoms observed in the
recessive forms of BH4D, such as hypotonia, develop-
mental delay, cognitive impairment, oculogyric crises
or epilepsy, occur extremely rarely in patients with
AD-GTPCHD.
R#4: (strong): In patients with dystonia, especially of
the lower limbs, with onset in the first or second decade
of life associated with diurnal fluctuation of symptoms
and normal development, possibly accompanied by par-
kinsonism, AD-GTPCHD should be considered.
Age of onset and age of diagnosis
Precise data on the age of disease onset and the age of
diagnosis could not be reliably gathered from a retro-
spective analysis of published case reports. However, up
to 40% of patients with BH4Ds can be asymptomatic
during the neonatal period. With increasing age, the per-
centage of asymptomatic patients decreases significantly
(except PCDD) [3].
BH4Ds presenting with HPA can be detected by NBS
and are therefore diagnosed early (between 2 and 14
days of life) [3]. The absence of HPA in SRD markedly
delays the diagnosis (mean age at diagnosis 8.9 years), al-
though the first symptoms may be apparent as early as
within the first 18 months of life [3, 21, 27, 32]. In AD-
GTPCHD patients, disease onset is typically during the
first decade of life (mainly between 3 to 9 years of age),
although very rarely patients may present with dystonia
and/or developmental delay in the first 12–18months
[33, 34]. Disease onset in the second decade is also com-
mon. The average delay in diagnosis (in the time before
easily accessed diagnostic whole exome sequencing) has
been stated to be around 10 years [10].
Phenotype correlations with genotype or biochemical
phenotype
There are many different variants described in all BH4D
genes (Table 1). The detailed list is constantly updated
(see https://www.ncbi.nlm.nih.gov/clinvar/, http://www.
hgmd.cf.ac.uk or https://omim.org, search term “tetrahy-
drobiopterin” assessed December, 2019) and is beyond
the scope of this guideline project.
For PCDD, AR-GTPCHD, DHPRD, and PTPSD, there
are no consistent reports on genotype–phenotype correl-
ation. For AD-GTPCHD, there is certain heterogeneity:
Some publications discuss and exclude genotype-
phenotype correlation [35, 36]. Others describe different
large heterozygous GCH1 deletions with high penetrance
and association with multifocal dystonia and adult onset
in a Taiwanese DRD population [37]. In 43 patients with
SRD with 16 different SPR mutations, no clear geno-
type–phenotype correlation was documented [21].
Diagnosis: laboratory tests
Key diagnostic test: newborn screening
The pattern of increased Phe concentrations with re-
duced Tyr concentrations resulting in elevated phenyl-
alanine/tyrosine ratio detects all forms of HPA in
national newborn screening (NBS) programs [38].
Among the BH4 disorders, AR-GTPCHD, PTPSD,
DHPRD and PCDD classically present with HPA. De-
tailed results of NBS are available from 15 AR-
GTPCHD, 305 PTPSD, 46 DHPRD, and 18 PCDD cases.
Patients with AR-GTPCHD can be missed on NBS due
to missing HPA [19, 39, 40], while those published cases
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where HPA on NBS in DHPRD was not detected, are
more likely due to unreliable (historical) methods of Phe
detection (e.g. Phenistix [41, 42];). In comparison, NBS
was negative in two cases of PTPSD. However, retro-
spective re-evaluation revealed that the analysis was
most likely done by the semiquantitative bacterial inhib-
ition assay (Guthrie method), known to cause false-
negative results [43, 44]. In PCDD, all reported cases
presented with HPA. The level of HPA in NBS can vary
widely and is not indicative of a specific BH4D. PCDD
tends to be associated with lower Phe levels. No correl-
ation has been observed between the NBS Phe level and
the subsequent disease course.
Today, levels of Phe and Tyr are measured by tandem
mass-spectrometry (MS). The measurement of Phe in
dried blood spot (DBS) is a temperature and light stable
method, and available in many countries worldwide.
R#5 (strong): Newborn screening for PKU should be
performed in all countries following standardized proto-
cols and using modern laboratory techniques to identify
elevated levels of Phe. Detection of HPA may be the first
clue for underlying AR-GTPCHD, PTPSD, DHPRD or
PCDD.
R#6 (strong): NBS is not a suitable diagnostic tool for
AD-GTPCH and SRD.
R#7 (GPP): Patients diagnosed with HPA on NBS
should be referred to a specialized metabolic centre for
further diagnostic evaluation and prompt initiation of
treatment.
Key diagnostic test: blood phenylalanine (plasma/serum)
As in DBS, increased Phe concentrations in plasma point to
all forms of HPA [38]. Although the measurement of Phe
concentrations in DBS with MS has several advantages over
plasma analysis (easier to obtain and transport, minimal
sample preparation, stable metabolites in DBS), there is evi-
dence that Phe quantification in plasma is more precise
[45]. Comparison studies of simultaneous measurement of
Phe concentration using a MS or an ion-exchange chroma-
tography protocol in either DBS or plasma samples indi-
cated that Phe concentrations were up to 26% lower if
measured in DBS [46].
R#8 (conditional): Any newborn screening result of
HPA should be confirmed by quantification of the Phe
level in plasma before treatment is started.
Key diagnostic test: Pterins in DBS and urine
Apart from BH4Ds, the differential diagnosis of HPA in-
cludes phenylalanine hydroxylase (PAH) deficiency,
DNAJC12 deficiency, high natural protein intake, prema-
turity, and liver disease. One option to further investi-
gate the underlying cause of HPA is the analysis of
pterins in DBS or urine. With the exception of AD-
GTPCHD and DHPRD, each BH4D presents with a
specific pterin pattern [47] (Fig. 2). AR-GTPCHD reveals
low biopterin and neopterin (in DBS and urine). In
PTPSD, neopterin is highly elevated along with low
biopterin (DBS and urine). In PCDD, primapterin is high
in urine, while biopterin has been reported to be low to
normal, and neopterin normal to high. Primapterin is
not elevated in any other BH4D and cannot be reliably
detected in DBS. In DHPRD, no consistent pattern of
biopterin and/or neopterin levels DBS or urine has been
documented: Most patients showed normal neopterin
with low to normal biopterin, although a few had normal
to elevated neopterin with high biopterin. In some pa-
tients both elevated biopterin and neopterin were
observed.
In AD-GTPCHD, low to normal values of biopterin and
neopterin have been reported in urine [48]. There is no
data on DBS. Sepiapterin is typically elevated in SRD, but
can be detected in urine only via an additional assay [49].
Biopterin and neopterin are typically normal in DBS and
urine in this disorder.
In comparison to the analysis of DBS, the measurement
of pterins in urine is more sensitive due to their higher con-
centrations in urine. On the other hand, the DBS method
provides easy sample handling and low transport costs [50].
It should be noted that pterins in urine are more suscep-
tible to degradation by light and high temperature than in
DBS. Collection and handling of both urine and DBS
should be performed by strictly following standardized pro-
cedures to ensure the accuracy of results. Both analyses are
available in specialized laboratories, mainly in first world
countries.
R#9 (strong): Strong recommendation for the analysis
of pterins in urine or DBS in patients with HPA on NBS.
Pterin analysis cannot rule out DHPRD (see below for en-
zyme activity measurements).
Be aware that analysis in urine is more sensitive than
in DBS, and that pathological patterns suggestive for
PCDD and SRD can only be detected in urine. In the
case of clinical suspicion, sepiapterin in urine must be
requested separately.
Note: Depending on availability and financial re-
sources, a primary genetic HPA workup can be consid-
ered (see below).
R#10 (conditional/research): Analysis of pterins in
urine can be considered in patients with clinical suspicion
of AD-GTPCH, where cerebrospinal fluid (CSF) studies or
molecular genetic testing are not available.
Key diagnostic test: DHPR enzyme activity
DHPRD can be reliably detected only by the determin-
ation of DHPR activity in DBS [51]. In the literature,
DHPR enzyme activity results in DBS were reported in
31 cases with AR-GTPCHD, in 1 case with AD-
GTPCHD, 176 cases with PTPSD, 151 cases with
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Fig. 2 (See legend on next page.)
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DHPRD, and 6 cases with PCDD. The analysis resulted
in a reduced DHPR activity only in DHPRD while being
normal in the other BH4Ds.
Although conclusions drawn from case reports and
small case series per se have low levels of evidence, the
findings were highly consistent in DHPRD. Of 151 re-
ported patients, 150 had a reduced or even absent DHPR
activity in DBS in every laboratory. In one patient, nor-
mal DHPR activity was documented. However, the au-
thors in that case consider technical problems to have
been highly likely, and reported that the parents did not
consent to a repetition of the analysis [52].
Measurement of DHPR activity in DBS is a light and
temperature sensitive method. It is available in special-
ized laboratories, mainly in first world countries.
R#11 (strong): Strong recommendation for the ana-
lysis of DHPR enzyme activity in DBS in patients with
HPA in NBS and/or in case of clinical suspicion of dis-
orders of BH4 deficiency.
Key diagnostic test: lumbar puncture (HVA, 5-HIAA,
neopterin, biopterin and sepiapterin and 5-MTHF in CSF)
Secondary to the shortage of the essential cofactor BH4
and the consecutively impaired function of the aromatic
amino acid hydroxylases, levels of 5-hydroxyindoleacetic
acid (5-HIAA) and homovanillic acid (HVA) in CSF are
typically significantly low in the BH4Ds, apart from
PCDD [17]. Notably, normal levels of HVA and 5-HIAA
have been documented in published AD-GTPCHD cases
(normal HVA in 27% (5 of 18 patients) and normal 5-
HIAA in 45% (9 of 20 patients) and in approx. 37–41%
of PTPSD cases [25, 53–55], probably representing a
milder phenotype. In DHPRD, normal levels of HVA
were reported in 9/130 patients while normal 5-HIAA
levels were found in 2 patients [24, 56–58]. All patients
with SRD had low levels of HVA and 5-HIAA. However,
some patients were reported to have initially normal
CSF HVA and 5-HIAA levels associated with a mild
phenotype, before evolving to a more severe phenotype
associated with low CSF HVA and 5-HIAA levels.
Additional evaluation of CSF neopterin, total biopterin
or BH4, and dihydrobiopterin (BH2) makes it possible to
biochemically differentiate between the different BH4Ds
by determining the relevant level of the metabolic block
in BH4 biosynthesis or regeneration. Both neopterin and
biopterin are low in AR-GTPCHD and in most cases of
AD-GTPCHD, but in the latter an isolated neopterin de-
crease seems to be more frequent [59, 60]. High neop-
terin with low biopterin points to PTPSD. Depending on
the analytical method, elevated total biopterin or ele-
vated BH2 points to DHPRD or SRD. Sepiapterin is
highly elevated in SRD and normal in all other BH4Ds.
Pterins in CSF are normal in PCDD.
5-methyltetrahydrofolate (5-MTHF) is one of the natur-
ally occurring folates containing a methyl carbon unit at-
tached to the N5 nitrogen atom [61]. The methyl unit in 5-
MTHF is essential for various processes in CNS including
the methylation of homocysteine to methionine, and the
formation of S-adenosyl-methionine (SAM). The latter is
required for more than 100 methylation reactions in cells,
including methylation of DNA, RNA, neurotransmitters,
lipids, hormones, and drug metabolites [61]. Due to the
close interplay between pterin and folate metabolism, de-
pletion of 5-MTHF in the CSF can occur in BH4Ds. Hereby
specifically the DHPR enzyme supports dihydrofolate re-
ductase (DHFR) to maintain folate in its active “tetrahydro”
form, in which it is capable of serving as a precursor for the
universal methyl donor substance SAM [62].
5-MTHF measurements in CSF were reported in 15 cases
with AR-GTPCH, 83 cases with PTPSD, 63 cases with
DHPRD and 3 cases with SRD. No reports were available
for AD-GTPCH and PCDD. In DHPRD, low levels of 5-
MTHF were reported [63] while patients with AR-GTPCH
and PTPSD have normal to low levels. 5-MTHF in SRD
was normal. In addition, high-dose L-Dopa/carbidopa sup-
plementation can reduce CSF 5-MTHF levels [64].
(See figure on previous page.)
Fig. 2 Diagnostic flowchart for differential diagnosis of BH4Ds with and without HPA.
1Consider genetic HPA workup depending on availability
and financial resources. The gene panel should include the QDPR, GCH1, PTS PCBD1, SPR genes as well as DNAJC12. For GCH1, consider MLPA if
Sanger sequencing is negative. 2The analysis in urine is more sensitive than in DBS and pathological patterns suggestive for PCDD and SRD can
only be detected in urine but not in DBS. 3Primapterin measurement in urine is only elevated in PCDD. 4Aminoacids in CSF are not required for
diagnosis of BH4Ds.
5CSF analysis should always include standard measurements (cell count, proteins, glucose and lactate). 6Recommendation
against measurements of HVA, 5-HIAA, 5-MTHF, and pterins in CSF in the case of PCDD. (*) A diagnostic L-Dopa trial should be limited to children
with symptoms suggestive of dopa-responsive dystonia or to situations where biochemical and genetic diagnostic tools are not available. If the
diagnostic L-Dopa trial is positive but the results of CSF biochemical and/or molecular genetic testing are not compatible with AD-GTPCHD or
SRD, further aetiologies for dopa responsive dystonia should be considered (e.g. juvenile parkinsonism (PARK2gene)). (**) Can be considered if
available. See text for more detailed information. Abbreviations: 5-HIAA, 5-hydroxyindoleacetic acid; 5-MTHF, 5-methyltetrahydrofolate; AA: amino
acids; AD−/AR- GTPCHD: guanosine triphosphate cyclohydrolase I deficiency; BH4, tetrahydrobiopterin; Bio: biopterin; CSF: cerebrospinal fluid; DBS:
dry blood spot; DHPR: q-dihydropteridine reductase; DHPRD, dihydropteridine reductase deficiency; HVA, homovanillic acid; MRI, magnetic
resonance imaging; N: normal; NBS: newborn screening; Neo: neopterin; NR: not reported; PAH: phenylalanine hydroxylase; Phe: phenylalanine;
PKU: phenylketonuria; Prim: primapterin; PTPSD, 6-pyruvoyltetrahydropterin synthase deficiency; SRD: sepiapterin reductase deficiency; Tyr:
tyrosine; u: urine; (+) = positive effect; (−) = no or no clear effect
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Analysis of dopamine and serotonin metabolites,
pterins, and 5-MTHF is performed in a limited number
of specialized laboratories. An online list of iNTD affili-
ated laboratories is available at the website www.intd-on-
line.org. Collection and analysis of CSF metabolites
requires the use of strict protocols and timing to avoid
analytical pitfalls [65]. Since normal results of single pa-
rameters may be found, CSF analyses should always con-
sist of a combination of monoamines (ideally including
3-O-methyldopa (3-OMD), l-3,4-dihydroxyphenylalanine
(L-Dopa), 5-hydroxytryptophan (5-HTP)), pterins, and
5-MTHF to ensure the correct interpretation of results
by pattern recognition. Patients’ medication at the time
of CSF sampling should be documented.
R#12 (strong): CSF analysis of HVA, 5-HIAA, pterins
and 5-MTHF is a reliable diagnostic method to differen-
tiate between the BH4Ds. Specific measurements in CSF
should include the core metabolites HVA, 5-HIAA,
pterins and 5-MTHF. Pterins can be used to differentiate
between different BH4Ds.
R#13 (strong): Recommendation against measurement
of HVA, 5-HIAA, 5-MTHF, and pterins in CSF for
PCDD.
R#14 (GPP): CSF measurements should always in-
clude standard measurements (cell count, protein, glu-
cose, lactate) considering possible differential diagnosis
e.g. infection or inflammation of different origin [65].
Collection and handling of CSF should be performed by
strictly following standardized procedures to ensure cor-
rect interpretation of results.
Key diagnostic test: genetic testing
For all enzymes involved in the biosynthesis or regener-
ation of BH4, gene variants have been reported in many
patients (see https://www.ncbi.nlm.nih.gov/clinvar/).
Therefore, mutation detection is the preferred method
for diagnosis confirmation or in case of non-conclusive
metabolite profiles. All BH4Ds are autosomal recessive
disorders apart from AD-GTPCHD where heterozygous
mutations in the GCH1 gene cause childhood-onset
dopa-responsive dystonia with diurnal fluctuation [66].
In GCH1, sequence alterations have been found by
Sanger sequencing in only 50 to 60% of clinically typical
AD-GTPCHD cases [67]. Since deletions can occur in
GCH1, the detection requires special methods such as
quantitative real-time polymerase chain reaction (qPCR)
or multiple ligation-dependent probe amplification
(MLPA) [35].
Recently, biallelic mutations in the DNAJC12 gene,
coding for a heat shock co-chaperone of the HSP40 fam-
ily, have been identified in individuals with mild HPA
and a broad spectrum of clinical symptoms including
dystonia, speech delay, axial and limb hypertonia, par-
kinsonism and psychiatric features [12]. Treatment with
sapropterin dihydrochloride and/or neurotransmitter
precursors L-Dopa/decarboxylase (DC) inhibitor and 5-
HTP had beneficial effects and resulted in the preven-
tion of neurodevelopmental delay in individuals treated
before the onset of symptoms [11, 12]. Exclusion of
DNAJC12 gene variants has therefore been suggested to
be mandatory in all patients with HPA where pterins,
DHPR activity and PAH gene analysis are normal [11].
DNA (from peripheral blood cells, tissues, cultured
cells or dried blood spots) is the preferred sample.
The increasingly broad availability of multi-gene
panel testing or next-generation sequencing (NGS)
provides a time- and cost-effective approach that will
assist clinicians to identify the correct diagnosis in
patients with absent biomarkers or atypical clinical
features. The identification of disease-causing muta-
tions facilitates accurate prenatal diagnosis, determin-
ation of the carrier status of family members, and
genetic counselling [68, 69].
R#15 (strong): Biochemical diagnosis of BH4Ds
should be confirmed by molecular genetic analysis.
R#16 (conditional): Depending on the availability and
the time to result, multi-gene panel testing or next-
generation sequencing can be the first step to further
differentiate the underlying pathophysiology in patients
with HPA or to confirm BH4Ds in patients with a suspi-
cious clinical presentation. The gene panel should in-
clude the QDPR, GCH1, PTS PCBD1, SPR, PAH and
DNAJC1 genes. If results of genetic testing are unre-
markable, consider other known neurotransmitter disor-
ders (e.g. tyrosine hydroxylase deficiency, aromatic l-
amino acid decarboxylase deficiency), especially in the
case of non-HPA.
Concluding statements regarding key diagnostic tests
R#17 (strong): There are 5 core diagnostic keys for
identifying BH4D (see Fig. 2 Diagnostic flowchart):
 Elevated Phe levels in NBS or selective diagnostic
work-up in patients with AR-GTPCHD, PTPSD,
DHPRD or PCDD.
 Abnormal levels of biopterin, neopterin, primapterin
and/or sepiapterin in urine and DBS.
 In DHPRD: decreased DHPR enzyme activity in
DBS.
 Low CSF levels of 5-HIAA, HVA in combination
with altered levels of CSF pterins and/or high
sepiapterin in CSF.
 Confirmation of pathogenic variants in the GCH1,
PTS, SRP, QDPR and PCBD1 genes.
Other diagnostic tests: blood prolactin
Dopamine acts as an inhibitor of prolactin secretion.
Therefore, prolactin in blood can be elevated in
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dopamine biosynthesis disorders [17]. Elevated prolactin
was found in 22 PTPSD [25, 70, 71], and 3 DHPRD cases
[72]. Prolactin was found normal in AD-GTPCHD subjects
[73]. In SRD, no reports on elevated prolactin levels were
available [21, 23, 74]. For AR-GTPCHD and PCDD, no lit-
erature evidence was available.
There are further notable reasons for increased prolac-
tin levels in blood such as physiological or pathological
endocrine conditions, hypothalamus and pituitary disor-
ders, systemic disorders, infections, drug related changes,
and post-ictal status [75, 76].
Measurement of prolactin in blood is an inexpensive
laboratory test that is available worldwide.
R#18 (research): Prolactin measurement can be part
of the diagnostic work-up for suspected dopamine defi-
ciency, but it has low sensitivity and specificity. Recom-
mendation for further research on prolactin levels at
diagnosis and during drug treatment.
Other diagnostic tests: serotonin (whole blood)
Whole blood serotonin was reported to be low in only 5
cases of SRD [21, 77]. In all other BH4Ds, no literature
evidence was available. Due to the very limited number
of patients, it is not possible to draw conclusions about
the diagnostic accuracy of this test.
R#19 (research): The role of serotonin measurement
in diagnosis and treatment monitoring should be evalu-
ated in further research.
Other diagnostic tests: BH4 loading test
Determination of BH4-responsiveness in patients with
HPA can be done by oral BH4 loading test. The test was
initially also used to discriminate between patients with
elevated phenylalanine levels due to PAH deficiency and
patients with elevated Phe levels due to BH4D [78]. At
present, there is no uniform test procedure available and
test protocols vary considerably from short duration (8
h) to extended duration (48 to 78 h) with repeated BH4
administration [79, 80]. Comparably, BH4 doses used
vary from 2.5 mg to 20 mg/kg BW and higher.
A BH4 loading test was performed in 7 studies with >
15 AR-GTPCHD patients, 33 studies with 443 PTPSD
patients, in 22 studies with 161 DHPRD patients, and 7
studies with > 12 PCDD patients. All studies have a low
or very low level of evidence according to GRADE.
There is no literature evidence available for AD-GTPCH
and SRD. Regarding the effect of BH4 on Phe levels,
studies are conclusive, documenting a significant de-
crease in Phe concentration within the first 8–12 h fol-
lowing BH4 load in AR-GTPCHD, PTPSD and PCDD.
In contrast, patients with DHPRD show a less prominent
Phe reduction during the same time period [3, 81, 82].
Sample collection for the BH4 test is minimally inva-
sive. The test, however, requires blood sampling over 8-
12 h and placement of a nasogastric tube for patients
who refuse to take BH4 by mouth.
R#20 (Conditional): The oral BH4 loading test can be
considered in patients with HPA for the assessment of
BH4-responsiveness.
R#21 (GPP): Test procedures for measuring BH4 re-
sponsiveness can follow local recommendations for HPA
patients. The procedure usually consists of baseline as-
sessment of Phe concentration in blood at times − 24 h,
− 12 h, and 0 h (=basal measurement). This is followed
by the oral administration of 20 mg/kg BW of saprop-
terin dihydrochloride once daily, taken with a regular
meal on two consecutive days. Phe concentration in
DBS should be tested every 8 h for 72 h after exposure.
Other diagnostic tests: Phe loading test
Oral Phe loading has been used additionally for the dif-
ferential diagnosis of dystonia and BH4Ds [83–85]. Dur-
ing the test, hepatic phenylalanine hydroxylase is
stressed by an oral Phe intake. In the setting of partial
BH4 deficiency, conversion of Phe to Tyr is compro-
mised, resulting in an elevated Phe/Tyr ratio for up to 6
h. In addition, the physiological stimulation of BH4 bio-
synthesis via GTPCH feedback regulatory protein
(GFRP) by Phe is absent, and biopterin concentrations
remain low after Phe loading [86].
The available literature on Phe loading tests in patients
with BH4Ds is composed of 38 studies with > 31 AR-
GTPCHD patients, 13 studies with > 100 AD-GTPCHD
patients, one study on one PTPSD patient, 4 studies with 4
DHPRD cases and 4 studies with > 50 SRD patients. While
all studies constitute a low or very low level of evidence,
the conclusions that can be drawn are consistent: Plasma
Phe concentrations are elevated and tyrosine remains un-
changed resulting in an increased Phe/Tyr ratio. Further
discrimination from heterozygous PKU patients becomes
possible by adding the analysis of biopterin in plasma or
DBS. The use of specific paediatric cut-off values improves
test sensitivity and specificity [86]. However, test results do
not correlate with clinical disease severity [87].
Phe loading is a time-consuming procedure and re-
quires blood sampling over 4-8 h. In uncooperative pa-
tients, gastric tube placement may be required. The Phe
loading test should not be performed concurrently with
administration of BH4 [88].
R#22 (Conditional): The oral phenylalanine loading
test can be considered when there is clinical suspicion
for AR−/AD-GTPCHD and SRD, when first line diag-
nostic tests (CSF biogenic amines and pterins or genetic
studies) are not available.
Other diagnostic tests: L-Dopa loading test
A temporary therapeutic L-Dopa trial has been historic-
ally commonly used in children or adults with
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unexplained early-onset dystonia. However, there is a
paucity of knowledge available about the sensitivity and
specificity of this method. The present need for this test
has in addition been questioned given the increasing
availability of advanced biochemical, radiological and
molecular genetic investigations [89].
R#23 (GPP): The diagnostic L-Dopa trial should be
limited to children with features suggestive of dopa-
responsive dystonia such as lower limb dystonia with di-
urnal variation and absent HPA. Trial outcome should
be monitored by careful clinical assessment including
thorough (video supported) documentation of motor
dysfunction, autonomic dysfunction, and psychiatric
symptoms.
Other diagnostic test: lumbar puncture (amino acids in CSF)
Only 8 studies with 25 patients (22 cases of AR-
GTPCHD, 1 case of DHPRD and 2 cases of SRD) report
results of amino acids analysis in CSF. No data is avail-
able for AD-GTPCHD, PTPSD, and PCDD. Phenylalan-
ine was normal to high in AR-GTPCHD and high in
DHPRD [51]. PCDD and SRD had normal Phe [23, 51,
90, 91].
The measurement of amino acids in CSF is available
in many laboratories, mostly located in first world
countries.
R#24 (research): Amino acids in CSF are not required
for diagnosing BH4Ds. For a better understanding of the
pathophysiological role of elevated Phe levels in BH4Ds
under treatment, we recommend the measurement of
Phe in CSF for future research studies.
Other diagnostic test: lumbar puncture (other metabolites
in CSF)
Low nitrite/nitrate levels in CSF were reported in 12
cases of PTPSD, 9 cases of DHPRD, and in 1 case of SRD
[92]. Low 3-Methoxy-4-hydroxyphenylglycol (MHPG)
was found in 5 DHPRD [93, 94] and in 4 SRD [95–97]
cases. Low concentrations of 3-Methoxytyramine (3-
MT), 3,5-Dihydroxyphenylglycine (DHPG), and 3,4-
Dihydroxyphenylacetic acid (DOPAC) were observed in
1 DHPRD case [98]. Noradrenaline/epinephrine in CSF
was normal in 1 DHPRD [99] and 1 PCDD patient [100].
Dopamine in CSF was reported to be normal in 1 PCDD
case. 5-HTP in CSF was low in 2 SRD cases and normal
in 1 case, and L-Dopa was normal in 1 SRD case [95, 97].
No reports on these parameters were available for AD-
GTPCH and AR-GTPCH deficiency.
All of these analyses are available only in specialized
laboratories, mostly located in first world countries.
R#25 (research): Recommendation for research on
quantification of CSF biomarkers (including nitrite, ni-
trate, MHPG, 3-MT, DOPAC) when lumbar puncture is
performed for other clinical reasons.
Key diagnostic test: enzyme activity measurements
A strong recommendation for the analysis of DHPR en-
zyme activity in DBS in patients with HPA in NBS and/
or in case of clinical suspicion of disorders of BH4 defi-
ciency has been given above (R#11).
Enzyme activity essays are also available for the other
BH4D and their results are described for 26 AR-
GTPCHD, 23 AD-GTPCHD, 91 PTPSD, 53 SRD cases
as well as 7 cases with PCD deficiency. As material
source, skin fibroblasts, blood (erythrocytes, lympho-
cytes), liver tissue, and cerebral frontal lobe tissue were
chosen. In AR-GTPCHD, PTPSD and SRD, the enzyme
activities showed diagnostically relevant reduced concen-
trations [24, 41, 101–105]. The residual enzyme activity
does not correlate with the subsequent disease course. A
clear description of the methods and source of tissues
for cases of PCDD is not available.
R#26 (conditional): Conditional recommendation
against enzyme measurement in all other BH4 deficien-
cies for confirmation of the diagnosis since other less in-
vasive and more sensitive diagnostic options are
available.
Diagnosis: brain imaging
Cranial magnetic resonance imaging (cMRI) or com-
puter tomography (cCT) results were reported in more
than 100 patients with all variants of BH4Ds apart from
PCDD. All patients with AD-GTPCHD showed normal
results. The highest rate of abnormal brain imaging re-
sults was reported in patients with DHPRD (all 8 cMRI
abnormal, 22 out of 24 cCT abnormal). Neuroradiologi-
cal findings included brain atrophy, basal ganglia calcifi-
cations, white matter changes, ventricular dilatation,
areas of hypodensity, and global demyelinating signs
[3, 94, 106–112]. In PTPSD, 13/26 cMRI and 3/5
cCT were normal. Documented neuroradiological
findings were widespread delayed myelination, periven-
tricular hyperintensities, brain atrophy, and one case of
brain calcifications [3, 47, 113–115]. Very few brain im-
aging studies showed abnormal results in SRD (5/47
cMRI) and AR-GTPCHD (1/10 MRI) [21, 116]. For other
imaging modalities like dopamine transporter (DAT)-
scan, Fluorodeoxyglucose Positron-emission tomography
(FDG PET), and F-Dopa PET, published data is scarce.
The overall evaluation of all relevant brain imaging
changes did not reveal any specific pattern of cMRI ab-
normalities for BH4Ds. Therefore, brain imaging is not
required for the diagnosis of BH4Ds. However, cMRI is
typically performed in the work-up of a patient with
movement disorders and/or neurodevelopmental delay
in order to exclude other underlying diseases. Further-
more, following standards of good clinical care, neuro-
imaging is always indicated if there is an unexpected
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deviation in the clinical course of patient already diag-
nosed with a BH4D.
R#27 (conditional): Routine imaging of the brain is
not required to diagnose BH4Ds.
R#28 (GPP): In the work-up of patients with move-
ment disorders and/or neurodevelopmental delay, or in
case of an unexpected deviation of the clinical course in
patients with BH4D, cranial MR imaging should be
performed.
Diagnosis: prenatal diagnosis
If a confirmed diagnosis exists in an index patient, pre-
natal testing in following pregnancies is possible. The
early diagnosis is decisive for prenatally initiated treat-
ment like L-Dopa supplementation, which has been
shown to be beneficial in AR-GTPCHD patients [68].
Furthermore, the parents and physicians can prepare for
adequate peri- and postnatal management. The method
of choice is mutation analysis in chorionic villus samples
or in amniotic fluid cells [117]. Pterin analysis in amni-
otic fluid are also possible but not available as a routine
diagnostic procedure [118].
R#29 (strong): Molecular genetic analysis is the pre-
ferred prenatal testing method for all BH4Ds.
Treatment
First-line treatment
The long-term neurodevelopmental outcome of BH4D pa-
tients is strongly influenced by the early initiation of effect-
ive treatment [3], therefore therapy must not be delayed.
Based on evaluation of the literature, evidence exists for
(maintenance) drug therapy, including dosage and side ef-
fects, for Phe-reduced diet, sapropterin dihydrochloride, L-
Dopa with peripheral DC inhibitor (carbidopa or bensera-
zide), 5-HTP, folinic acid, dopamine agonists (DA), select-
ive monoamine oxidase (MAO) inhibitors (MAO-I),
anticholinergic agents, catechol-O-methyl transferase
(COMT) inhibitors, selective serotonin reuptake inhibitors
(SSRIs), benzodiazepines, melatonin, and botulinum toxin
injections. For L-Dopa without DC inhibitor, psychiatric
therapy, baclofen, and surgery treatment there was insuffi-
cient literature available to inform any recommendations.
Note: For all treatment options, the total body of evi-
dence in the literature was rated as low or very low.
Multiple studies referred to the same data basis within
the BIODEF database. Positive, neutral, and negative
(“side effects”) treatment effects are summarized in the
following sections. Detailed dose recommendations are
given in Table 4.
Dietary treatment
Phe-reduced diet The harmful effect of Phe accumula-
tion in blood and brain is best witnessed in untreated
patients with PKU who develop irreversible neurological
impairment and psychiatric symptoms if exposed to
HPA [5]. Although the precise pathogenesis of brain
dysfunction is still unclear, there is strong rationale for
reducing HPA and maintaining satisfactory low Phe
levels in all BH4Ds with HPA [120]. The two available
strategies to treat HPA are a Phe-reduced diet or
sapropterin dihydrochloride supplementation.
Phe-reduced diet was used in 5 AR-GTPCHD patients
in 5 studies, 103 PTPSD patients in 25 studies, 115
DHPRD patients in 40 studies, and 29 PCDD patients in
5 studies. Use of the Phe-reduced diet was not reported
in any patient with SRD or AD-GTPCHD.
There is no precise data available regarding the daily
Phe tolerance in patients with BH4D and no precise data
on the number of patients who, after being originally
treated solely with a Phe-reduced diet, later switched to
sapropterin dihydrochloride supplementation or a com-
bined Phe-reduced diet plus sapropterin dihydrochloride
treatment.
Clear positive effect of Phe-reduced diet on lowering
Phe levels was documented in the vast majority of pa-
tients. However, as HPA is only one of the pathophysio-
logical mechanisms in BH4Ds, Phe-reduced diet as
monotherapy in AR-GTPCHD, PTPSD, and DHPRD
failed to improve symptoms such as hypotonia, hyper-
tonia, developmental delay, dystonia, other involuntary
movements, sleep and mood disturbances or epileptic
seizures. In contrast, there are 2 reports of PCDD pa-
tients with muscular hypo/−or hypertonia and motor de-
velopmental delay who showed improvement following
treatment with a Phe-reduced diet only [53].
In the reviewed BH4Ds literature, no negative effects
of Phe-reduced diet have been documented. However,
unnecessary dietary restrictions should be avoided, and
daily Phe intake and tolerance closely monitored to
optimize the maximal natural protein intake. Symptoms
of Phe deficiency may include anorexia, listlessness, alo-
pecia, perineal rash, poor growth or even death [5].
Note: As Phe levels in PCDD have nearly always been
reported to be only mildly elevated, relaxation and dis-
continuation of Phe-reduced diet and/or sapropterin
dihydrochloride supplementation can be attempted after
the first year of life under careful monitoring of Phe
levels.
R#30 (strong): Phe control should be applied in
BH4Ds with HPA (AR-GTPCHD, PTPSD, DHPRD and
PCDD). Phe control may be achieved by Phe-reduced
diet or sapropterin dihydrochloride supplementation
(see below). Phe levels should be regularly monitored in
DBS or blood. Target ranges should be determined by
local recommendations for the dietary treatment of
PKU.
R#31 (strong): Phe-reduced diet should not be used
in BH4Ds without HPA (AD-GTPCHD and SRD).
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R#32 (strong): Phe-reduced diet should not be used
in monotherapy for the treatment of neurological symp-
toms in BH4Ds.
Drug treatment
Sapropterin dihydrochloride The rationale for supple-
mentation of sapropterin dihydrochloride, a synthetic
tetrahydrobiopterin analogue, is based upon the defect-
ive biosynthesis or recycling of this essential cofactor for
the aromatic L-amino acid hydroxylases in all types of
BH4Ds. The main effect of sapropterin dihydrochloride
supplementation lies within its marked impact on the
control of peripheral Phe levels. Animal studies have
demonstrated rather poor penetration of peripherally ad-
ministered sapropterin dihydrochloride across the
blood-brain barrier and an increase of total biopterin
only after supplementation with doses not applicable in
clinical practice [121, 122]. Data concerning BH4 uptake
into the human brain, and correction of dopamine and
serotonin metabolism following sapropterin dihy-
drochloride administration, are very limited too [122].
Although sapropterin dihydrochloride is more expensive
than a Phe-reduced diet and is still unavailable in some
(European) countries, it enables a markedly higher nat-
ural protein intake and offers a much more convenient
way to treat HPA. Pharmacokinetic studies indicate a
mean elimination time of around 4–7 h depending on
the population studied. It can be administered in one
daily quantity and the target Phe concentrations should
follow the national recommendation for the treatment of
PKU.
The literature search identified approximately 40 AR-
GTPCHD patients from 16 studies, 397 PTPSD patients
from 41 studies, 194 DHPRD patients from 19 studies
(see note below), 29 PCDD patients from 10 studies, and
10 SRD patients from 9 studies treated with sapropterin
dihydrochloride, while no AD-GTPCHD patient on
sapropterin dihydrochloride was identified.
Evaluation of specific treatment effects of sapropterin
dihydrochloride was hampered by the use of co-
treatment (L-DOPA/DC inhibitor, 5-HTP) in almost all
patients, except in PCDD. The assessment of the effects
of sapropterin dihydrochloride may therefore be biased.
Similar to a Phe-reduced diet, if co-administered with
neurotransmitter precursors, a sapropterin dihydrochlor-
ide treatment consistently improved almost all clinical
symptoms in PTPSD, DHPRD (see comment below),
and AR-GTPCHD, including movement disorders (dys-
tonia, oculogyric crises, choreoathetosis, tremor, hypo-
tonia, hypertonia, rigidity), epileptic seizures, sleep
problems, gastrointestinal disturbances (hypersalivation,
swallowing difficulties), anthropometric parameters, de-
velopmental delay, and behavioural abnormalities. In
addition, biochemical markers such as the concentration
of CSF neurotransmitter metabolites were positively in-
fluenced. In SRD patients, however, no clear clinical
benefit was reported [21, 96].
Experience of sapropterin dihydrochloride monother-
apy is mainly limited to mild forms of PTPSD with min-
imal or even absent clinical symptoms, and normal
levels of dopamine and serotonin metabolites in CSF
[44]. However, such patients need to be closely moni-
tored as evolution from a mild into a severe phenotype
can occur, requiring the full treatment regimen with
dopamine and serotonin precursors [123]. A handful of
patients experienced improvement in developmental im-
pairment, hypotonia, swallowing difficulties, hypersaliva-
tion, drowsiness or epileptic seizures when on
sapropterin dihydrochloride monotherapy.
If used as monotherapy, sapropterin dihydrochloride
has been reported in several cases to fail to improve or
prevent intellectual disability, movement disorders, sei-
zures or sleep problems, and it also did not affect the
levels of CSF neurotransmitter metabolites [22, 25, 44].
No negative effects related to sapropterin dihy-
drochloride administration have been reported in the lit-
erature reviewed. According to the official drug
information, patients may commonly (≥1/10) or very
commonly (≥1/100 to < 1/10) experience headaches, rhi-
norrhoea, pharyngolaryngeal pain, nasal congestion,
cough, diarrhoea, abdominal pain, dyspepsia or nausea.
Note: Based on the hypothesis that sapropterin dihy-
drochloride supplementation may lead to increased 7,8-
dihydrobiopterin (BH2) production and a decreased
BH4/BH2 ratio resulting in aggravation of disease sever-
ity by inhibiting the aromatic L-amino acid hydroxylases
or by increasing nitric oxide (NO) uncoupling and oxi-
dative stress, this treatment approach is currently con-
troversial in DHPRD [124, 125]. However, literature
evidence for these potential harmful effects is scarce and
based on cell experiments only [124]. In contrast, there
are 194 patients with DHPRD (15 studies) received BH4
supplementation published who did not show any clin-
ical or biochemical adverse effect that could be directly
related to BH4 supplementation. Furthermore, there is a
suggestion that restoration of the BH4 pool with BH4
supplementation may have a protective effect [125].
Therefore, there is no reliable justification to withhold
this therapeutic intervention from patients with DHPRD.
R#33 (strong): Phe control should be applied in
BH4Ds with HPA (AR-GTPCHD, PTPSD, DHPRD and
PCDD). Phe control is possible through a Phe-reduced
diet (see above) or through administration of sapropterin
dihydrochloride. Sapropterin dihydrochloride is the
treatment of choice in AR-GTPCHD, PTPSD, and
PCDD. It should be administered once daily and doses
should be titrated according to Phe levels. Phe levels
should be controlled in DBS or blood, and target ranges
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should follow local recommendations for the dietary
treatment of PKU. In PCDD, discontinuation of saprop-
terin dihydrochloride supplementation can be attempted
after the first year of life under careful Phe level
monitoring.
R#34 (conditional): In DHPRD, Phe-reduced diet and
not the supplementation of sapropterin hydrochloride is
nowadays considered the method of choice for the con-
trol of HPA. Since the available evidence against the use
of sapropterin dihydrochloride is scarce, sapropterin
dihydrochloride can be considered in DHPRD patients.
Phe levels should be controlled in DBS or blood, and
target ranges should follow local recommendations for
the dietary treatment of phenylketonuria.
R#35 (research): To better understand the patho-
physiological mechanism and metabolic consequences of
sapropterin dihydrochloride treatment in DHPRD and
also the effect of sapropterin dihydrochloride monother-
apy, we recommend further research on these topics.
L-Dopa with or without carbidopa/benserazide
BH4Ds result in significantly reduced dopamine avail-
ability in the CNS. L-Dopa, a dopamine precursor that is
converted to dopamine by the aromatic L-amino acid
decarboxylase (AADC) enzyme, has been widely used for
numerous indications in order to restore dopamine
homoeostasis. The addition of carbidopa or benserazide,
a peripheral DC inhibitor, blocks the peripheral decarb-
oxylation of L-Dopa. This results in increased L-Dopa
concentrations at the blood-brain barrier and also in re-
duced peripheral L-Dopa side effects.
The effect of L-Dopa/carbidopa was described in 197
AD-GTPCHD patients in 32 studies, in 45 AR-
GTPCHD patients in 18 studies, in 540 PTPSD cases in
36 studies, in 249 DHPRD patients in 45 studies, in 49
SRD patients in 25 studies, and in one 1 PCDD patient.
The effect of L-Dopa/benserazide was documented in
11 AD-GTPCHD patients in 6 studies, in 11 PTPSD pa-
tients in 2 studies and in 4 SRD patients in 4 studies.
For L-Dopa/benserazide treatment in AR-GTPCHD,
DHPRD, and PCDD, no literature evidence is available.
It is not possible to judge the effect of L-Dopa without
a DC inhibitor since for 162 AD-GTPCHD patients in
32 studies, 1 AR-GTPCHD patient in 1 study, 47 PTPSD
patients in 4 studies, 21 DHPRD patients in 7 studies,
and 1 SRD patient, it was not clearly stated whether L-
Dopa was used alone or in combination with a DC in-
hibitor. For PCDD, no literature evidence is available on
the use of L-Dopa without a DC inhibitor.
Note: Almost invariably, L-Dopa/DC inhibitor treat-
ment was initiated simultaneously with 5-
hydroxytryptophan treatment (apart from AD-
GTPCHD). Evaluating the impact of these drugs separ-
ately may therefore be problematic and biased.
Furthermore, the patients were concurrently treated with
sapropterin hydrochloride and on a Phe-reduced diet.
L-Dopa/DC inhibitor treatment in BH4D patients was
found to improve most disease-related symptoms in the
majority of studies. Positive treatment response corre-
lated inversely with the age at treatment initiation [3,
82], however, treatment non-responders were reported
too.
The positive effects of L-Dopa/DC inhibitor treatment
in BH4Ds were observed on almost all clinical endpoints.
Improvements in motor development, cognitive func-
tions, muscle tone abnormalities (hypotonia, poor head
control, hypertonia) and epileptic seizures were reported
in the largest proportion of patients. A positive effect
could also be observed on dystonia, including oculogyric
crises, dyskinesias and other movement disorders, par-
kinsonism, epileptic seizures, autonomic dysregulation
(temperature instability), gastrointestinal disturbances
(hypersalivation, swallowing difficulties), anthropometric
parameters (failure to thrive, growth retardation, micro-
cephaly), sleep problems, behavioural and psychiatric
disorders or delayed speech development. Additionally, a
positive effect of L-Dopa/DC inhibitor treatment was re-
ported on the level of various biochemical markers, in-
cluding urinary pterins, CSF neurotransmitter
metabolites and prolactin.
In some patients, however, regardless of the BH4D
type, even combined treatment with L-Dopa/DC in-
hibitor failed to improve either disease symptoms or
biomarker results.
Negative effects reported in BH4D patients receiving
L-Dopa/DC inhibitor treatment correspond to the ad-
verse effects generally observed with L-Dopa treatment.
The negative motor effects manifested mainly as dyskin-
esia and as motor fluctuations with on/off phenomenon.
Other movement disorders (tremor, chorea, myoclonic
jerks) were observed less frequently. Non-motor side ef-
fects of L-Dopa/DC inhibitor described included behav-
ioural and psychiatric symptoms (anxiety, delusions,
impulsivity, irritability, hyperactivity, mood fluctuations
or panic attacks), sleep disturbances, gastrointestinal
problems (nausea, vomiting, diarrhoea) and headaches.
The most commonly used ratio of L-Dopa to DC in-
hibitor is 4:1. The available literature doesn’t allow an
evaluation of whether the 4:1 preparation has a superior
effect compared to the 10:1 preparation. According to
published drug information, there is no known upper
dose limit for DC inhibitor or any specific side effects
described. In contrast, side effects of L-Dopa in the con-
text of DC inhibitor underdosing clearly justify sufficient
dosing.
From a pharmaceutical perspective, it is important
to mention that benserazide is unstable in the air.
During compounding, the substance oxidizes and can
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therefore become ineffective. Carbidopa, on the other
hand, is relatively stable. It can also be readily com-
pounded into a formulation suitable for children.
Theoretically, drug forms for the preparation of sus-
pensions are available. However, since there is no
uniform distribution in the suspension due to the un-
dissolved particles, it is not recommended to divide a
suspension. If a suspension is used, it should be ad-
ministered immediately after production.
R#36 (strong): L-Dopa should always be given in
combination with a DC inhibitor (4:1 ratio) and
should be the first line of treatment in AD-GTPCHD,
AR-GTPCHD, DHPRD, PTPSD, and SRD.
R#37 (strong): The L-Dopa/DC inhibitor starting
dose should be low, distributed in several daily dos-
ages and slowly titrated depending on the clinical
symptoms. In case of side effects, the timing and dos-
ing of medication may be adjusted individually. Refer-
ring to the normal range of dopamine metabolite
values in CSF, which is highest during the neonatal
and infantile period, the target treatment dose in all
infants (below 40 kg body weight) with BH4D (apart
from AD-GTPCHD) is 10 mg/kg BW/d (if clinically
tolerated). Some patients require higher doses. In AD-
GTPCHD, most patients obtain complete symptom
control with lower doses of L-Dopa /DC inhibitor.
5-Hydroxytryptophan Reduced bioavailability of sero-
tonin in the CNS in BH4Ds results from impaired
conversion of tryptophan to 5-HTP by tryptophan hy-
droxylase 2 (TPH2), for which BH4 is an essential co-
factor. The subsequent conversion of 5-HTP to
serotonin is carried out by the AADC enzyme, which
is unaffected in BH4Ds. This forms the pathophysio-
logical rationale for the supplementation of 5-HTP in
BH4Ds with a potential to correct the neurotransmit-
ter imbalance.
5-HTP was used in 41 AR-GTPCHD cases in 12 stud-
ies, in 4 patients with AD-GTPCHD in 1 study, in 542
PTPSD patients in 41 studies, in 93 DHPRD in 49 stud-
ies, 14 SRD patients in 19 studies, and in 1 PCDD
patient.
For all patients, except for one patient with PCDD,
overall clinical improvement on various endpoints was
reported.
Note: 5-HTP was used in combination with other
medications in all patients. 5-HTP treatment is often ini-
tiated simultaneously with L-Dopa/DC inhibitor and/or
sapropterin dihydrochloride /Phe-reduced diet, which
markedly hampers the assessment of the effects of 5-
HTP alone. 5-HTP treatment was started without L-
Dopa/DC inhibitor in only in a handful of patients; the
reported effects are inconsistent among the studies.
The observed positive effects of 5-HTP (at least in
co-administration with L-Dopa/DC inhibitor) include
improvement in almost all clinical endpoints includ-
ing acquisition of developmental milestones, cogni-
tion, tone and movement disorders, epileptic seizures,
swallowing difficulties and hypersalivation, speech de-
velopment, attention and behaviour, and mood (de-
pression). Sleep disturbances have been reported to
improve with 5-HTP treatment. Due to co-
medication, the improvement could, however, only be
clearly assigned to 5-HTP supplementation in very
few patients. Psychiatric and behavioural problems,
other symptoms often associated with serotonin defi-
ciency, were reported to improve in some patients as
well: In 4 AD-GTPCHD patients, depression improved
on 5-HTP in monotherapy or 5-HTP in combination
with serotonin agonists or serotonin reuptake inhibi-
tors [126]. Interestingly, during a 5-HTP shortage
lasting for 6 months, no obvious neurologic deterior-
ation could be observed in a cohort of 12 PTPSD pa-
tients [127].
As with L-Dopa/DC inhibitor treatment, 5-HTP ad-
ministration failed to improve symptoms in some
patients.
The most common adverse effects of 5-HTP are
gastrointestinal problems (nausea, vomiting, diarrhoea,
abdominal pain). Indeed, these symptoms necessitated
5-HTP discontinuation in some cases. Irritability, chor-
eoathetoid, dyskinetic or myoclonic movement disor-
ders, and sweating were observed, too. Given its co-
administration with L-Dopa/DC inhibitor, numerous
other adverse effects were observed, but from a patho-
physiologic standpoint, these are more likely to be re-
lated entirely or at least partially to L-Dopa rather than
to 5-HTP treatment.
R#38 (strong): From a biochemical standpoint, 5-HTP
is considered a first line treatment in BH4Ds. In patients
with DHPRD, PTPSD, and SRD, benefits clearly out-
weigh adverse effects, leading to a strong recommenda-
tion for the use of 5-HTP in these disorders. For PCDD
and AD-GTPCHD, no recommendation can be given
due to lack of evidence.
R#39 (conditional): For AR-GTPCHD, desirable con-
sequences probably outweigh undesirable consequences,
thus forming a conditional recommendation for the use
of 5-HTP in this disorder.
R#40 (strong): 5-HTP should follow initiation of the
L-Dopa/DC inhibitor treatment. There is no clear evi-
dence for a starting dose; however, it should be lower
than the L-Dopa dose (e.g. Table 4). It should not be
changed at the same time as L-Dopa to clearly distin-
guish clinical effects. Start with a low dose and titrate
slowly as dictated by clinical symptoms. Use a peripheral
decarboxylase inhibitor (e.g. by administering at the
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same time as L-Dopa/DC inhibitor) to reduce (gastro-
intestinal) side effects.
Folinic acid Cerebral folate deficiency may occur in
BH4Ds, most prominently in DHPRD. However, there is
risk of development of cerebral folate depletion in the
other BH4Ds too, as long-term administration of L-Dopa
in high doses can result in reduced availability of these
methyl groups due to the methylation of L-Dopa to 3-O-
methydopa (3-OMD) [51].
The therapeutic use of folinic acid in BH4Ds is re-
ported in more than 14 AR-GTPCHD cases in 3 studies,
in approximately 40 PTPSD patients in 2 studies, in 262
DHPRD cases in 37 studies, and in 1 SRD patient. There
is no literature available for the use of folinic acid in
PCDD and AD-GTPCHD.
Assessment of the clinical efficacy of folinic acid sup-
plementation is substantially influenced by the use of
various co-medications in the vast majority of patients
or by the lack of data on the clinical course following
the introduction of folinic acid.
The positive effects of folinic acid (in combination
with other medications) included improvement in motor
and cognitive function in movement disorders or epilep-
tic seizures. The rare reports on the change of a patient’s
clinical status after introducing folinic acid claimed im-
provement in overall condition, in seizure control and
neurologic status, and in the CSF neurotransmitter pro-
file [63, 128, 129]. In the only DHPRD patient treated
solely with folinic acid monotherapy (apart from Phe-
reduced diet), improvement of tremor, drowsiness, hy-
persalivation, and in the frequency of myoclonic seizures
was noticed [130].
In some patients, the addition of folinic acid did not
change the clinical status or improve the CSF neuro-
transmitter profile [24, 125].
In 2 patients, adverse effects consisting of vomiting, ir-
ritability, and changes in sleep pattern were observed;
however, these patients were treated concurrently with
other medications. Otherwise, there are no reports of
negative effects that could be related to the addition of
folinic acid supplementation to the treatment regimen.
It is important to note that folic acid, a non-naturally
occurring form of folate used to fortify food, is contrain-
dicated in this condition, as it competitively binds to the
folate receptor alpha (FRα), resulting in reduced 5-
MTHF transport into the brain [61].
R#41 (strong): Folinic acid supplementation should be
used in patients with DHPRD. Note: Cerebral folate defi-
ciency may even be aggravated by the administration of
folic acid!
R#42 (conditional): Folinic acid supplementation
should be considered in any patient with BH4D found to
have low 5-MTHF concentration in CSF.
Second-line treatment
Drug treatment
Dopamine agonists Dopamine agonists (DA) exert their
function by direct postsynaptic activation of dopamine re-
ceptors. Ergot-derived DAs that have a strong serotoner-
gic (5HT2b) receptor interaction (cabergoline and
pergolide) are associated with cardiac valvulopathy and
other fibrotic adverse events, and have been removed from
the market in many countries. Ergot-derived DA without
5HT2b agonist action (bromocriptine) have an overall
lower risk. However, pulmonary, retroperitoneal, and
(peri) cardial fibrosis have been described with a dose-
effect relationship [131]. Non-ergot DAs (apomorphine,
piribedil, pramipexole, ropinirole and rotigotine) seem to
possess a very low and statistically insignificant risk of fi-
brotic complications and are preferred in clinical practice
[131]. Potential benefits of DAs are related to their longer
bioavailability in the synaptic cleft leading to equalised L-
Dopa/DC inhibitor stimulation of dopaminergic terminals
in the striatum [132].
The use of DA in BH4Ds as complementary drug
treatment was documented in 12 AD-GTPCH patients, 5
PTPSD and 5 DHPRD patients, and in 8 patients with
SRD. No AR-GTPCHD or PCDD patient receiving DA
has been reported.
The most commonly used DA was pramipexole (16
patients) followed by bromocriptine (10 patients) and
cabergoline (5 patients). Reports on the use of other DA
are very scarce and limited to AD-GTPCHD.
Among BH4D patients, DAs were most commonly
used concomitantly with L-Dopa/DC inhibitor, 5-HTP,
sapropterin dihydrochloride, Phe-reduced diet or folinic
acid treatment, rarely in monotherapy or in combination
with a MAO inhibitor. In the majority of patients, the
use of DAs allowed for a significant reduction of L-
Dopa/DC inhibitor doses, less frequent daily administra-
tions and an improvement of the residual motor symp-
toms (if specified, mainly parkinsonian symptoms such
as tremor, bradykinesia, hypomimia, dysarthria etc.).
Furthermore, DAs were reported to beneficially affect L-
Dopa/DC inhibitor adverse effects, namely L-Dopa in-
duced dyskinesia and mood swings [133–139].
Reported DA side effects comprise mainly behav-
ioural/psychiatric disorders; impulse control disorders,
including pathological gambling, compulsive buying, and
hypersexuality, were reported almost exclusively under
pramipexole treatment [136]. Symptoms were dose-
dependent and subsided after adequate treatment adjust-
ment. In a few patients, worsening of motor symptoms
(dystonia, dyskinesias), weight loss or unspecified nega-
tive events led to the discontinuation of DA treatment
[32, 137]. No fibrotic complications have been described.
R#43 (conditional): Dopamine agonists can be con-
sidered as second line treatment in all BH4Ds (apart
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from PCDD) in combination with first line treatment
options if residual symptoms persist despite L-Dopa/DC
inhibitor treatment or if dose-limiting L-Dopa/DC in-
hibitor- associated adverse events occur. Non-ergot de-
rived DAs (pramipexole, ropinirole, rotigotine) or ergot-
derived DA without 5HT2b agonist action (bromocrip-
tine) are preferred.
R#44 (GPP): Cardiac screening before and during
treatment with bromocriptine (ergot derived DA) is indi-
cated because of the potential risk of cardiac fibrosis.
Selective monoamine oxidase (MAO) inhibitors MAO
inhibitors prevent the breakdown of dopamine and sero-
tonin in the synaptic cleft. The effect of selective MAO in-
hibitors was described in more than 2 AR-GTPCHD cases
in 2 studies, in 4 AD-GTPCHD patients in 4 studies, in
roughly 19 PTPSD patients in 5 studies, in 8 DHPRD
cases in 4 studies, and in more than 7 SRD patients in 7
studies. For PCDD, no evidence is available. All studies de-
scribe the effect of selective MAO inhibitors only in com-
bination with L-Dopa/DC inhibitor, dopamine agonists, 5-
HTP, sapropterin dihydrochloride, selective serotonin re-
uptake inhibitors (SSRIs), Phe-reduced diet or folinic acid.
Selegiline (n = 36 cases) and rasagiline (n = 1 case) are the
only selective MAO inhibitors used [31]. No studies were
found on tranylcypromine or phenelzine. The majority of
studies described an improvement in at least one clinical
endpoint (e.g. dystonia, fatigability, sleep, motor develop-
ment or seizure control) or in lowering L-Dopa doses; an
effect on motor fluctuations (on-off phenomena) was de-
scribed, too. Some studies reported an unclear outcome.
Side effects of MAO inhibitors alone (diarrhoea or consti-
pation, drowsiness or insomnia, dry mouth) were not re-
ported. One patient with SRD developed dyskinesia after
adding SSRI to the treatment regimen [104].
R#45 (conditional): MAO inhibitors can be consid-
ered as second line treatment in AR-GTPCHD, AD-
GTPCHD, PTPSD, DHPRD, and SRD in combination
with first line treatment options although little or no evi-
dence is available.
R#46 (GPP): The members of the guideline group
consider selective MAO inhibitor a treatment option in
case of dose-related symptom fluctuations and drug-
induced dyskinesia or motor fluctuations. Use should be
guided by availability of the drug and experience of the
treating physician. The members of the guideline group
judged MAO inhibitors to have fewer side effects com-
pared to dopamine agonists.
Third-line treatment
Drug treatment
Anticholinergic drugs Anticholinergic drugs (e.g. tri-
hexyphenidyl) are commonly used to treat movement
disorders, especially dystonia and parkinsonism. The
current hypothesis is that anticholinergic drugs influence
the relative imbalance between dopaminergic and cho-
linergic pathways, however, the exact mechanism of ac-
tion is unclear [140]. The effect of anticholinergic drugs
in BH4Ds was described in 17 patients with AD-
GTPCHD in 8 studies and in 4 patients with SRD in 3
studies. For AR-GTPCHD, PTPSD, DHPRD, and PCDD,
no published evidence is available.
Trihexyphenidyl (> 15 cases), benztropine (> 2 cases),
and methixene (> 1 case) were the anticholinergic drugs
used [139]. In AD-GTPCHD, most patients first received
L-Dopa/DC inhibitor. Trihexyphenidyl was added due to
incomplete control of symptoms on L-Dopa/DC inhibi-
tor alone and/or due to dyskinesia at higher L-Dopa/DC
inhibitor doses [141, 142]. In the majority of AD-
GTPCHD patients, a moderate to excellent effect on
dystonia and tremor was noted; however, not all patients
exhibited clinical benefit. For SRD, positive effects of
benztropine supplementation are described in two pa-
tients without providing further details. Typical anti-
cholinergic side effects (dry mouth, dry eye, blurred
vision (pupil dilation), constipation, urinary retention,
reduced sweating) were not described in BH4Ds.
R#47 (conditional): Consider anticholinergic agents
as third-line treatment in AD-GTPCHD and, based
on the pathophysiological background, also in AR-
GTPCHD, SRD, PTPSD, and DHPRD patients in
case of incomplete control of symptoms with L-
Dopa/DC inhibitor. For PCDD, no recommendation
is possible due to lack of evidence.
COMT inhitibors The inhibitors of catechol-O-methyl
transferase (COMT) prevent the action of this enzyme,
which is involved in the breakdown of catecholamines
and, thus, has a direct impact on the pharmacodynamic
and pharmacokinetic properties and the behaviour of
levodopa. By this mechanism, COMT inhibitors have the
potential to increase the availability of catecholamine
neurotransmitters in the CNS, particularly dopamine.
The indication for this add-on treatment would be to re-
duce motor fluctuations associated with L-Dopa treat-
ment. The only evidence available in the literature for
treatment of BH4Ds is for entacapone.
Treatment with entacapone was described in 4 AD-
GTPCHD cases in 3 publications, 8 PTPSD cases in 4
studies, in 14 DHPRD patients in 3 studies. For AR-
GTPCHD, PCD, and SRD, no literature evidence is
available. There are no descriptions of COMT inhibitor
monotherapy in the BH4D cohort. All patients were
treated concurrently with L-Dopa/DC inhibitor, DA, 5-
HTP, sapropterin dihydrochloride, Phe-reduced diet or
folinic acid.
The assessment of clinical efficacy was yet again prob-
lematic due to insufficient data on the clinical course
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after initiating COMT inhibitors. Clear positive effects
could not be obtained for PTPSD and AD-GTPCHD.
Decreased prolactin levels were documented after enta-
capone introduction in DHPRD. No specific side effects
commonly related to COMT inhibitors (dyskinesia,
hyper−/hypokinesia, gastrointestinal problems with nau-
sea, constipation or diarrhea) were reported among
BH4D patients. General dose recommendations can be
used.
R#48 (conditional): The use of COMT inhibitors can
be considered as third line treatment in all BH4Ds apart
from PCDD. The members of the guideline group con-
sider COMT inhibitors as a treatment option in patients
suffering from motor fluctuations with L-Dopa/DC in-
hibitor treatment.
Selective serotonin reuptake inhibitors (SSRI) SSRIs
act by decreasing the presynaptic reuptake of serotonin,
which leads to its prolonged bioavailability in the synap-
tic cleft and better postsynaptic receptor occupancy. The
rationale for their use in BH4Ds is the presence of symp-
toms attributable to serotonin deficiency such as psychi-
atric and behavioural disorders and sleep problems.
The use of SSRIs (sertraline, fluoxetine and others)
was reported in 1 patient with AR-GTPCHD, 11 patients
with AD-GTPCHD in 4 studies and in 4 patients with
SRD in 5 studies. For PCD, DHPRD and PTPSD no lit-
erature evidence is available.
For all patients with SRD, improvement of disease re-
lated symptoms (including improved alertness, sleep
time and dystonia) were documented [96, 104]. In 10
out of 11 patients with AD-GTPCHD, depression im-
proved [126, 143]. One patient with AR-GTPCHD expe-
rienced worsening of depression [26], and one patient
with SRD had akathisia and dyskinesia/myoclonus while
treatment concurrently with a MAO inhibitor (selegi-
line) [104].
R#49 (conditional): There is a conditional recommen-
dation for the use of SSRIs in AD-GTPCHD for psychi-
atric symptoms.
R#50 (conditional): Based on the current evidence,
no definitive recommendation can be given for the use
of SSRIs in AR-GTPCHD, PTPSD, DHPRD, and SRD.
Guideline group members consider SSRIs in individual
cases as third line treatment with caution of possible
side effects if all first- and second-line treatment options
have, over an adequate amount of time, shown to be in-
sufficient to control symptoms. For PCDD, no recom-
mendation is possible due to lack of evidence.
R#51 (GPP): Caution: According to the guideline
group members, the combination of 5-HTP and SSRI
treatment, specifically in very high doses, can induce
serotonin syndrome!
Melatonin From a pathophysiological perspective, mela-
tonin supplementation for disorders of sleep induction is
reasonable because melatonin is formed from serotonin
and, therefore, may be decreased in a BH4 deficient
state.
Apart from 2 patients with SRD, who were reported to
have reduced night time dystonia and improved sleep
transition, there is very limited evidence for the use of
melatonin in BH4Ds [21, 104]. In the 2 studies with low
or very low level of evidence, no side effects have been
reported.
R#52 (conditional): There is a pathophysiological ra-
tionale to consider a trial of melatonin in all BH4D pa-
tients facing sleep induction problems before using
other sleep-inducing medications. Prior to this, an
optimization of 5-HTP supplementation should be
reached (except in AD-GTPCH and PCDD).
Acute drug treatments
Baclofen Baclofen is a CNS depressant and skeletal
muscle relaxant used to treat spasticity. In the literature,
there is only one SRD case published in whom baclofen
was used. However, no clear description of its clinical ef-
fect is provided [104]. No recommendation is possible
due to lack of evidence.
R#53 (GPP): The application of baclofen could be
considered in patients with complications due to spasti-
city. The decision should be based on individual clinical
judgment. See the guideline on diagnosis and manage-
ment of cerebral palsy in young people [144].
Benzodiazepines Benzodiazepines belong to the
broader generally accepted treatment regimen of dys-
tonia. However, for BH4Ds, there is no satisfying evi-
dence for the use of benzodiazepines. A single patient
with SRD is described who experienced no change in the
duration of oculogyric crisis with benzodiazepine treat-
ment [97]. However, the guideline group members de-
scribe beneficial effects on prolonged oculogyric crisis in
some patients (personal communication).
R#54 (GPP): Current evidence for benzodiazepine
treatment in BH4Ds is very scarce but a treatment at-
tempt can be considered in specific settings, e.g. in sus-
tained oculogyric or dystonic crises, always based on
individual clinical judgement.
Anti-epileptics The literature evidence for the use of
anti-epileptic treatment in BH4Ds is primarily available
for DHPRD. The use of various anti-epileptic drugs,
most commonly phenobarbital and phenytoin, and al-
ways combined with other medications, was reported in
14 cases from 9 studies [93, 94, 145]. Notably, folinic
acid supplementation was reported to improve epileptic
seizures in DHPRD, too [94, 146, 147]. One patient with
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SRD treated with valproic acid was reported, but no de-
tails regarding the clinical course were provided. For the
other BH4Ds, the specific antiepileptic drugs used are
usually not specified.
R#55 (GPP): Epileptic seizures are not a cardinal clin-
ical symptom of BH4Ds and should be distinguished by
reliable diagnostic approaches from oculogyric crisis or
dystonic jerks. If required, any antiepileptic treatment
can be used according to the specific indications for dif-
ferent seizure types.
Other supportive therapies
Botulinum toxin injections Botulinum toxin injections
are commonly used to treat focal dystonia. However,
since there are only 3 patients with AD-GTPCHD re-
ported in whom botulinum toxin injections were used,
there is very limited evidence for its application in
BH4Ds. There are no patients described with botulinum
toxin injections as monotherapy. In one case, botulinum
toxin injections were used before the diagnosis of the
underlying BH4D. 2 other cases were concurrently
treated with L-Dopa/DC inhibitor [142, 148], and with
trihexyphenidyl in 1 case, which did not resolve dystonic
symptoms completely (writer’s cramp, blepharospasm,
and retrocollis). All patients improved with botulinum
toxin injections; however, the co-administration of other
medications does not permit evaluation of the effect of
botulinum toxin alone. Side effects were not reported in
the literature. Dose and application procedure should
follow specific guidelines [149].
R#56 (conditional): Botulinum toxin injections should
be considered as an option in the case of persistent focal
dystonia in AD-GTPCHD if all first- and second-line
treatment options have, over an adequate amount of time,
shown to be insufficient to control these symptoms. For
AR-GTPCHD, DHPRD, PTPSD, SRD, and PCDD, there is
no recommendation possible due to lack of evidence.
Multidisciplinary treatment Although there are not
sufficient studies or reports on the impact of multidis-
ciplinary treatment in BH4Ds available, involvement of a
broad team with specialists in physiotherapy, speech
therapy, occupational therapy, feeding and nutritional
assessment, and (neuro-) psychological treatment should
always be part of the complex care provided to BH4D
patients to improve patient care, prevent secondary
complications, and promote neurological development.
Psychiatric therapy There is very limited evidence for
the use of psychiatric therapy in the cohort of BH4D pa-
tients. It is presumed that at least some patients with psy-
chiatric disturbances received psychiatric pharmacothera
py; however, the literature is scarce. There are 2 published
cases of adult patients with AD-GTPCHD who received
electroconvulsive therapy (ECT) [150, 151]. One of the pa-
tients with psychosis [151] developed a neuroleptic malig-
nant syndrome due to haloperidol treatment followed by a
prolonged catatonic state, which required ECT. In the
other patient, a combination of SSRI and 5-HTP did not
prevent the emergence of a delusional depression; he was
therefore treated with ECT. ECT therapy had a positive ef-
fect in both cases. Side effects of ECT are only mentioned
in one case: after the third and fourth treatment sessions,
the patient developed postictal disorientation and agita-
tion lasting about 30min [150]. Overall, no recommenda-
tion for a specific psychiatric therapy for the treatment of
psychiatric disorders in BH4Ds is possible due to lack of
evidence.
Experimental therapies
New experimental therapies are listed at https://clinical-
trials.gov.
Drugs to avoid in BH4 disorders
Drugs with antiemetic and antipsychotic properties, act-
ing as central dopamine antagonists, should be avoided
in BH4Ds since they have the potential to worsen symp-
toms of dopamine deficiency [152]. Metoclopramide
should not be used for the treatment of nausea. Tri-
methoprim/sulfamethoxazole should be avoided be-
cause it is reported to cause parkinsonian symptoms in a
confirmed patient with DHPRD [146]. This patient was
co-treated with L-Dopa/carbidopa and 5-HTP when
treatment with trimethoprim-sulfamethoxazole was initi-
ated (folinic acid was added afterwards). The adverse ef-
fects reported in this patient were clearly related to the
initiation of the antibiotic and their disappearance was
related to discontinuation of the treatment [146]. Due to
the inhibitory effect of methotrexate on DHPR and the
interaction with dihydrofolate reductase (DHFR), this
treatment may lead to HPA and early neurotoxicity, pos-
sibly combined with folate deficiency [153].
Prenatal treatment
Dopamine signalling is important already for intra-
uterine (brain) development [154]. Prenatal oral treat-
ment with L-Dopa/carbidopa to the mother of a genetic-
ally confirmed AR-GTPCHD foetus was shown to
prevent development of the severe phenotype related to
biallelic GCH1 mutations [68].
R#57 (research): Prenatal treatment with levodopa
can be beneficial. Since the experience of prenatal treat-
ment in BH4Ds is based on single case studies with low
to very low evidence, it would be desirable to develop a
protocol for further treatment attempts in a controlled
and standardized trial.
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Follow-up, transition and special situations
Follow-up visits
There are no reports available on standardized follow-up
visits in the BH4D patient cohort. Therefore, recommen-
dations can only be based on clinical experiences or
good clinical practice. Comparable to other inborn er-
rors of metabolism [5, 155], for all BH4Ds apart from
PCDD life-long, systematic follow-up is recommended
to achieve optimal development, to prevent or avoid
treatment side-effects, and to evaluate quality of life. In
addition, it is not known if and when long-term compli-
cations occur. Regular standardized follow-ups allow
early identification of patients presenting with such dis-
ease related or treatment-related complications.
R#58 (GPP): BH4D patients should be seen at least
yearly by a (child) neurologist with experience in move-
ment disorders or neurometabolic disease, ideally in a
multidisciplinary setting. Infants and young children
who require frequent dose adjustments during the
course of initial dose titration and due to weight gain
need to be seen more frequently (e.g. infants every 3
months; older children at least every 6 months)!
The follow-up visits should include the evaluation of:
– Phe-reduced diet (if applicable): Daily amount of
Phe, intake of amino acid mixture, amino acids in
plasma, full blood count, ferritin, parathormone,
calcium, phosphate, alkaline phosphatase, vitamin
B12
– Current medication: Regular intake? Symptoms of
over−/underdose?
– Neurological symptoms: Motor milestones,
seizures, oculogyric crises, vegetative symptoms
(sweating, fever, nausea, vomiting, stool frequency,
micturition frequency, sleep, behaviour), eating
habits, speech development
– General medical history: Anthropometric data?
Infections? Vaccinations? Narcotics or alcohol
abuse?
– Integration and inclusion measures (if applicable)
– Kindergarten, school, education, occupation
– ECG and/or echocardiography (if under treatment
with dopamine agonists).
– Neuropsychological development
Although there are no studies or reports on the need
for repeated measurement of CSF metabolites as part
of ongoing treatment monitoring, CSF analysis of
HVA, 5-HIAA, and 5-MTHF can be helpful for drug
dose titration or for clarification of otherwise unex-
plainable clinical irregularities. This is especially true
for younger children in whom the spectrum of
(neurological) symptoms can be broader or more dif-
ficult to assess.
R#59 (GPP): Consider CSF analysis of HVA, 5-HIAA,
and 5-MTHF for drug dose titration or for clarification
of otherwise unexplainable clinical irregularities in all
BH4Ds apart from PCDD. For the lumbar puncture
standard oral treatment should be interrupted as short
as possible.
Transition
As in many other inborn errors of metabolism, there is a
paucity of literature regarding transition from childhood
to adulthood in the BH4Ds. However, a successful transi-
tion to adult care requires the coordinated cooperation
of many disciplines. A transitional consultation with the
participation of paediatric and adult neurological institu-
tions is very valuable [156]. During the transition
process, the following aspects should be considered
among others: Role changes of patients, parents and
caregivers, active involvement of stakeholders in the
planning and decision-making processes, comprehensive
knowledge about the illness and its course.
R#60 (GPP): Begin planning early for transition of
BH4D patients to adult care in specialized centers.
Multidisciplinary care should be continued.
Anaesthesia
Reports on anaesthesia in BH4D patients are very scarce
in the literature, and do not indicate any particular risks.
From the metabolic perspective BH4D patients do not
require any special precautions and anaesthesia can fol-
low standardized procedures. No specific anaesthetic
drugs need to be avoided.
R#61 (GPP): Anaesthesia in BH4D patients may follow
standard protocols. After the operative procedure stand-
ard oral treatment should continue as soon as possible.
Genetic counselling
On the grounds that BH4Ds are inherited metabolic dis-
orders, it is good clinical practice to offer genetic coun-
selling to parents and/or patients. In addition, molecular
genetic analysis is the preferred prenatal testing method
for all BH4Ds (see R#29).
R#62 (strong): All patients or parents of patients with
BH4Ds should be offered standard genetic counselling if
available in local care settings.
Pregnancy
There are few cases in the literature reporting obstetric
and paediatric outcomes in pregnancies of patients with
BH4Ds [157]. It is important to control disease-related
symptoms, adjust the treatment if needed, and monitor
the development of the foetus. Therefore, close supervi-
sion by a multidisciplinary team (dietitian, (neuro) meta-
bolic consultant, neurologist, gynaecologist, geneticist) is
essential during the course of pregnancy and afterwards.
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R#63 (strong): Intensive supervision during and after
the pregnancy by a multidisciplinary team should be
provided.
Patient advocacy groups
Currently, there are the following non-profit volunteer
organizations, representing children and families who
are affected by a paediatric neurotransmitter disease in-
cluding BH4Ds:
– Pediatric Neurotransmitter Disease Association
(www.pndassoc.org) - USA
– Spanish neurotransmitter diseases association “De
neu” (www.deneu.org) - Spain
– German group for patients and parents with all
kinds of neurotransmitter related disorders (www.
dig-pku.de/wcf/index.
php?neurotransmitterstoerungen-nts/) - Germany
– Organization to support families with children
suffering from neurotransmitter diseases (www.
hrabrisa.rs/en/) - Serbia
Regular updates on patient advocacy groups can be
found under https://intd-online.org/patients/.
Conclusion
This is the first consensus guideline for the diagnosis
and management of BH4 deficiencies. All recommenda-
tions are based on the available literature evidence and
were phrased in a transparent consensus process by the
iNTD guideline working group. The guideline is
intended for clinicians, metabolic biochemists and para-
medical specialists involved in the care of patients with
BH4 deficiencies. It will help to harmonize clinical prac-
tice and to standardize and improve care for BH4 defi-
cient patients.
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